Emil D. Kakkis

2019

In 2019, Emil D. Kakkis earned a total compensation of $6.6M as President and Chief Executive Officer at Ultragenyx Pharmaceutical, a 36% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$479,808
Option Awards$2,650,784
Salary$714,000
Stock Awards$2,702,000
Other$39,887
Total$6,586,479

Kakkis received $2.7M in stock awards, accounting for 41% of the total pay in 2019.

Kakkis also received $479.8K in non-equity incentive plan, $2.7M in option awards, $714K in salary and $39.9K in other compensation.

Rankings

In 2019, Emil D. Kakkis' compensation ranked 1,491st out of 13,971 executives tracked by ExecPay. In other words, Kakkis earned more than 89.3% of executives.

ClassificationRankingPercentile
All
1,491
out of 13,971
89th
Division
Manufacturing
535
out of 5,695
91st
Major group
Chemicals And Allied Products
163
out of 2,194
93rd
Industry group
Drugs
129
out of 1,880
93rd
Industry
Pharmaceutical Preparations
96
out of 1,392
93rd
Source: SEC filing on April 29, 2020.

Kakkis' colleagues

We found four more compensation records of executives who worked with Emil D. Kakkis at Ultragenyx Pharmaceutical in 2019.

2019

John Pinion

Ultragenyx Pharmaceutical

Chief Quality Officer and Executive Vice President, Translational Sciences

2019

Shalini Sharp

Ultragenyx Pharmaceutical

Chief Financial Officer

2019

Camille Bedrosian

Ultragenyx Pharmaceutical

Chief Medical Officer

2019

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officer and Executive Vice President

News

You may also like